Internal Medicine, Rheumatology · Burleson, TX
NPI
1154641587
Since 2010
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
11803 South Fwy, Suite 210
Burleson, TX, 76028
Phone (817) 293-2944
Groups this clinician bills Medicare through
Medicare paid, 2024
$127K
18,861 services
Medicare patients, 2024
346
Average age 73
Drug cost, 2024
$3.5M
5,788 prescriptions
Company payments, 2025
$2,617
From 18 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Rosy Rajbhandary was code J1010 (injection, methylprednisolone acetate, 1 mg), 2,321 times for 32 patients. In total Rosy Rajbhandary billed 18,861 services in 15 codes, and Medicare paid $127K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-06-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 2,321 | 32 | $0.10 | $233 |
| 99214 Office E&M - Established | Office | 643 | 317 | $78.15 | $50K |
| 99204 Office E&M - New | Office | 120 | 120 | $109.14 | $13K |
| 96372 Injection Administration | Office | 33 | 23 | $9.80 | $323 |
| 20551 Musculoskeletal | Office | 16 | 13 | $41.11 | $658 |
| J1030 Injection, methylprednisolone acetate, 40 mg | Office | 12 | 12 | $4.62 | $55.44 |
By year: 2022 $70K for 904 services; 2023 $71K for 2,134 services; 2024 $127K for 18,861 services.
Medicare prescription drug claims, 2024
In 2024, the drug Rosy Rajbhandary prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 1,367 prescriptions and refills. In total Rosy Rajbhandary wrote 5,788 Medicare prescriptions that cost $3.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 1,367 | 3,130 | 376 | $54K |
| Methotrexate Methotrexate Sodium | 543 | 1,246 | 141 | $13K |
| Leflunomide Generic | 361 | 823 | 107 | $17K |
| Prednisone Generic | 345 | 571 | 189 | $1,755 |
| Gabapentin Generic | 296 | 644 | 72 | $5,447 |
| Allopurinol Generic | 270 | 692 | 72 | $2,302 |
| Meloxicam Generic | 260 | 514 | 94 | $1,174 |
| Folic Acid Generic | 222 | 537 | 63 | $1,660 |
| Humira(Cf) Pen Adalimumab | 166 | 173 | 18 | $1.3M |
| Cyclobenzaprine Hcl Generic | 165 | 351 | 54 | $1,952 |
| Sulfasalazine Generic | 160 | 372 | 43 | $3,855 |
| Vitamin D2 Ergocalciferol (Vitamin D2) | 159 | 324 | 47 | $1,694 |
| Colchicine Generic | 141 | 288 | 41 | $23K |
| Enbrel Sureclick Etanercept | 99 | 99 | Under 11 | $753K |
| Ibuprofen Generic | 98 | 133 | 34 | $1,357 |
Brand drugs: 688 claims; generic drugs: 5,100 claims; opioid claims: 42.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Rosy Rajbhandary $2,617 ($2,617 in general payments such as food, travel and fees) from 18 companies. The largest payer was Abbvie Inc. with $728.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 41 | $728 |
| Amgen Inc. AMGN | 33 | $685 |
| GlaxoSmithKline, LLC. GSK | 10 | $224 |
| Novartis Pharmaceuticals Corporation NVS | 13 | $187 |
| Janssen Biotech, Inc. JNJ | 10 | $174 |
| UCB, Inc. UCB.BR | 10 | $165 |
| Genzyme Corporation SNY | 3 | $80.35 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $57.45 |
| E.R. Squibb & Sons, L.L.C. BMY | 3 | $56.03 |
| Genentech USA, Inc. ROG.SW | 2 | $49.08 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.